ORANGEBURG, S.C. — Hillary Rodham Clinton has long declined to endorse legalized medical or recreational marijuana at the federal level, but on Saturday, she added more specifics to her proposal to increase research into medical marijuana.
Clinton said that she supports removing marijuana from a list of Schedule I drugs, a classification that prevents federally-sponsored research into its effects. As a Schedule I drug, marijuana is classified among the most dangerous drugs that the federal Drug Enforcement Agency regulates.
“We haven’t done research, why? Because it’s considered a Schedule I drug,” Clinton said during a town hall meeting at Claflin University in South Carolina on Saturday. “I’d like to move it from Schedule I to Schedule II.”
The addition to her position on marijuana brings her in line with two other Democratic presidential rivals, Vermont Sen. Bernie Sanders and former Maryland governor Martin O’Malley, who both oppose marijuana’s designation as a Schedule I substance.
2016 presidential candidates: How 420-friendly are Hillary and Jeb? Pot advocacy group gives report card
Lawmakers agree on a message for feds: On marijuana, state lawmakers across U.S. tell feds to butt out
Election 2016: Learn more about what GOP and Democratic presidential candidates are saying about marijuana
Congress: Get caught up on federal legislation for medical marijuana, banking and more
NEW: Get podcasts of The Cannabist Show.
Subscribe to our newsletter here.
Watch The Cannabist Show.
According to the Drug Enforcement Agency, Schedule I drugs are “defined as drugs with no currently accepted medical use and a high potential for abuse. Schedule I drugs are the most dangerous drugs of all the drug schedules with potentially severe psychological or physical dependence.”
Clinton has repeatedly said that she believes states are the “laboratories of democracy” on the marijuana issue and that she would like to see more research into the health effects of medical marijuana.
“I want to see how it works before we do a national plan for the federal government,” Clinton said.
Specifically, on Saturday, she said that more information is needed to determine safe dosages, the efficacy of certain varieties of the drug, and potential complications with other drugs.
Before her announcement, Clinton’s critics noted that the DEA’s classification of marijuana as a Schedule I drug makes it more difficult for research to be approved.
Clinton will also lift restrictions on obtaining marijuana for medical studies, by allowing researchers to obtain the drug through licensed suppliers in states where medical marijuana is legal.
Other marijuana advocates say moving the drug to Schedule II is not enough. Marijuana users and businesses would still risk federal penalties for using and selling the drug.
“The rescheduling of marijuana is a step in the right direction, but only going down to Schedule II is mostly a symbolic move,” said Tom Angell, chairman of the pro-marijuana group Marijuana Majority. “It may make research slightly easier, but on its own wouldn’t do anything to protect seriously ill people who are using marijuana in accordance with state laws from being harassed by the DEA.”
“Only changing the federal criminal statutes can effectively do that,” he added.
O’Malley also supports moving marijuana to the Schedule II list. Sanders is the only presidential candidate who has proposed removing marijuana altogether from the schedule of controlled substances regulated by the DEA.